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Learning Objectives 
•  Describe the rationale for the belief that 
opioids have no maximum dose 
•  Describe the data supporting the rationale 
that high doses of opioids increase toxicity. 
•  Describe the data supporting the rationale 
that high doses of opioids do not improve 
outcomes. 
•  Identify potential safety concerns with 
patients taking high doses of opioids 
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The Opioid Pendulum 
Stringent	  Criteria,	  
Limited	  Use	  of	  Opioids	  
Pain	  is	  Undertreated	  
Liberal	  Use	  of	  Opioids	  
Hoﬀman	  RS.	  Inadequate	  pain	  control	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  opioid	  abuse:	  It	  is	  Kme	  for	  the	  pendulum	  to	  swing.	  Am	  J	  Health	  Syst	  Pharm	  2014;71:1537	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State	  Board	  Members	  
Belief	  Opioid	  Use	  
Acceptable	  &	  Lawful	  for	  
CNCP	  	  
	  1991	  –	  12%	  
	  1997	  –	  33%	  
	  2004	  –	  67%	  
Gilson	  AM,	  et	  al.	  J	  Pain	  
2007;8:682-­‐691.	  
1987	  
MS	  	  ConKn	  FDA	  approval	  
1995	  
OxyConKn	  FDA	  approval	  
Portenoy	  R,	  et	  al.	  Pain	  1986;25:171-­‐186.	  
“ScienKﬁc	  launching	  pad	  for	  the	  pain	  
management	  movement.”	  
	  -­‐Barry	  Meier.	  Pain	  Killer.	  p64	  
MMWR.	  2011.	  60(43):1487-­‐1492	  
Opioid Use (and Misuse) Too Prevalent.  
States (FL) crack down 
Johnson	  H,	  et	  al.	  MMWR	  2014;63(26):569-­‐74	  
Pendulum Swinging Back?  
•  FL pain patients struggling 
to find pharmacies with 
opioids in stock 
•  “They just don’t have the 
medications because they 
run out [of] their allocation 
within the first week.” 
–  Chris Young, chronic pain 
sufferer 
•  “I turn away sometimes 20 
people a day.” 
–  Bill Napier, pharmacist 
–  Owner, Panama Pharmacy 
Kanner	  RM,	  Portenoy	  RK.	  J	  Pain	  Sympt	  Manag	  
1986;1(2):87-­‐89	  
hgp://hereandnow.wbur.org/2015/08/04/pill-­‐
mill-­‐crackdown	  	  Accessed	  August	  11,	  2015	  
Guideline Recommendations 
•  VA/DoD 
–  Consider referral for doses exceeding 200mg/day  MED  
•  Washington state 
–  Doses should not exceed 120mg MED without patient 
demonstrating functional improvement or referral 
•  Canada 
–  200mg/day MED = “watchful dose” (Canadian guidelines) 
•  American Pain  Society/American Academy of Pain Medicine 
–  200mg/day MED (“high” dose) warrants reassessment/monitoring 
•  CDC Opioid prescribing guidelines (draft) 
–  Caution above 50 mg/day; avoid > 90 mg/day 
How High Can You Go? 
Opioid Tolerance 
•  In theory, opioid doses can be continually 
titrated upwards 
•  Tolerance develops to most opioid-
mediated effects  
–  NOT constipation 
Money	  W.	  On	  the	  eﬀects	  of	  large	  doses	  of	  opium	  in	  	  a	  case	  of	  diabetes	  
mellitus.	  Med	  Chir	  1814;5:236-­‐8	  
Money	  W.	  On	  the	  eﬀects	  of	  large	  doses	  of	  opium	  in	  	  a	  case	  of	  diabetes	  
mellitus.	  Med	  Chir	  1814;5:236-­‐8	  
High dose opium (1814) 
•  Patient presented with polydipsia, polyuria, and 
“pain in the region of his kidneys.” 
•  Admitted to Northampton Infirmary in January 
1814 
–  “was cupped in the back and bled in the arm” 
•  No apparent effect other than “the removal of the pain in the 
loins.” 
•  Feb. 10th began taking 1 grain of opium Q HS 
–  By Mar. 1st was taking 24 grains of opium daily 
–  “very little inconvenience was felt from these large 
doses of opium so long continued.” 
Early Hospice Data (St. 
Christopher’s, London) 
•  Descriptive cohort study of 500 patients with advanced malignant 
disease 
•  Pain treated Q 4 hours 
–  Diamorphine 2.5 mg (initial dose) ß Heroin! 
–  Cocaine HCl 10mg 
–  Ethyl alcohol 95% 2.5mL 
–  Syrup (66% sucrose in water) 5 mL 
–  Chloroform water QS to 20mL 
•  Results 
–  “no single optimal or maximum effective dose” 
–  “tolerance not a practical problem” 
–  “psychological dependence does not occur” 
–  Physical dependence manageable 
–  Long term use (> 2 weeks) associated with higher doses (p < 0.001) 
Twycross	  RG.	  Int	  J	  Clin	  Pharmacol	  1974;9(3):184-­‐198	  
Early Hospice Approach  
(Royal Victoria Hospital, Montreal) 
•  Utilized Brompton mixture 
–  Morphine instead of diamorphine 
–  Dosing 
•  Starting dose of 2.5 to 5mg q 4 hours ATC 
•  Dose titration q 48 to 72 hours 
–  2.5, 5, 10, 15, 20, 30, 40, 60, 90, 120 
–  120mg q 4 hours = 720mg/day 
•  No systematic reporting of efficacy or toxicity 
•  Adverse effects described 
–  Sedation (transient) 
–  Nausea/vomiting (phenothiazine coadministration) 
–  Constipation 
–  Tolerance-dependence  
•  Dose increases felt to be secondary to clinical deterioration  
Mount	  BM,	  et	  al.	  Canadian	  Med	  Assoc	  J	  1976;115:122-­‐124.	  
Pharmacokinetic Study of 200mg 
Morphine CR Tablet 
•  Methods: Crossover study (n = 25) 
–  Advanced malignancy 
–  Stable on 400mg/day PO morphine 
–  Randomized to 100mg or 200mg CR tablet 
•  Results 
–  Dosing ranged from 400 to 2000 mg/day 
–  PK parameters similar 
–  Pain control (VAS) similar 
–  “No unpredictable adverse effects occurred..” 
•  73% reported sedation; 41% reported N/V 
–  “..rate of reporting of volunteered side effects was low." 
Hanks	  GW,	  et	  al.	  J	  Pain	  Symptom	  Manage	  1995;10:6-­‐12	  
PK,	  pharmacokineKc	  
VAS,	  visual-­‐analog	  scale	  
N/V,	  nausea/vomiKng	  
Cancer Pain Data: Morphine 
•  Cochrane review (n = 4,241, 62 studies) 
•  “Morphine is an effective analgesic for cancer pain.” 
–  Visual analog scale (VAS) most commonly used outcome 
•  Average daily dose: 100 – 250mg (range: 25 – 
2000mg) 
•  “…but the randomized trial literature is small given the 
importance of this medication.” 
•  No measurement of function 
•  Adverse events 
–  GI toxicity most commonly reported 
–  No mention of concerns of respiratory depression or 
overdose 
Wiﬀen	  PJ,	  et	  al.	  Cochrane	  Database	  Syst	  Rev.	  2013	  
Cancer Pain Data: Oxycodone 
•  Cochrane review (n = 1,390, 17 studies) 
•  Similar pain relief to morphine, other opioids (VAS) 
•  Average daily dose (reported in 9/17 studies)  
–  21 MED (Imanaka 2013) 
–  60 MED (Parris 1998) 
–  69 MED (Mercadante 2010) 
–  135 MED (Bruera 1998) 
–  135 MED (Gabrail 2004) 
–  150 MED (Mucci-LoRusso 1998) 
–  150 MED (Salzman 1999) 
–  180 MED (Hagenn 1997) 
–  180 MED (Heiskanen 1997) 
•  No measurement of function 
•  Toxicity similar to morphine, other opioids 
–  No safety signals 
Schmidt-­‐Hansen	  M,	  et	  al.	  Cochrane	  Database	  Syst	  Rev.	  2015	  
But those were all Cancer Pain studies… 
Cancer Pain 
•  Assumed to be terminal 
•  Neuropathy a common 
toxicity of chemotherapy 
•  Generally prone to 
infection 
•  Pain localized to tumor 
locale or diffuse as 
disease progresses 
Noncancer pain 
•  Long term life 
expectancy? 
•  Fibromyalgia & 
neuropathy common 
•  Competent immune 
system? 
•  Pain stabilizes 
“the scientific launching pad for the 
pain movement.”* 
*Barry	  Meier	  in	  Pain	  Killer,	  p.	  64	  
Case Series Demographics (n = 38) 
Dura'on	  (years)	   n	  
	  	  <	  2	   7	  
	  	  2	  –	  3	   10	  
	  	  4	  –	  5	   6	  
	  	  >	  6	   15	  
Dose	  	  
(mg,	  MED)	  
n	  
	  	  <	  30	   11	  
	  	  30	  –	  60	   14	  
	  	  61	  –	  90	   0	  
	  	  91	  –	  120	   2	  
	  	  121	  –	  150	   2	  
	  	  151	  –	  180	   1	  
	  	  >	  180	   3	  
	  	  Unknown	   5	  
Portenoy	  RK,	  Foley	  KM.	  Pain	  1986;171-­‐186	  
6	  (15.7%)	  received	  	  
>	  120	  mg	  MED	  
Diagnosis*	   n	  
	  	  Back	  pain	   14	  
	  	  Facial,	  abdominal	  
pelvic	  or	  extremity	  
pain	  
9	  
	  	  Other	   15	  
*All	  non-­‐malignant	  pain	  
Opioid	   n	  
	  	  Oxycodone	  	   12	  
	  	  Methadone	   7	  
	  	  Levorphanol	   5	  
	  	  Methadone/oxy	   3	  
	  	  Propoxyphene	   2	  
	  	  Meperidine	   2	  
	  	  Others	   7	  
Case Series Results (n = 38) 
•  Efficacy 
–  “comfort enhanced” in 24 of 38 (63%) 
•  “adequate” pain relief (29%); “partial” pain relief (34%) 
•  Toxicity 
–  “no episodes of clinically significant adverse 
effects” 
•  e.g. acute overdose, respiratory depression, excessive 
sedation, myoclonus 
–  2 episodes of abuse 
•  1 patient with history of psychosis 
•  1 patient with history of oxycodone abuse 
Portenoy	  RK,	  Foley	  KM.	  Pain	  1986;171-­‐186	  
Portenoy & Foley Conclusion 
“..a remarkably positive response in this population. 
 
Nonetheless, few patients had dramatic improvement in 
employment status or family relationships… 
 
Furthermore, psychological distress…was neither markedly 
ameliorated nor exacerbated. 
 
These data suggest opioid maintenance therapy can provide 
acceptable, though often incomplete, analgesia for a significant 
group of refractory patients, but is no panacea for the profound 
impairment commonly occurring in this population.” 
Portenoy	  RK,	  Foley	  KM.	  Pain	  1986;171-­‐186	  
Take Home Points 
•  No apparent increased risk in the 15% on 
high-dose opioids (> 120 MED) 
–  Reasonable safety results, especially 
considering 50% took opioids 4+ years 
•  Potential endpoints for future study 
–  Employment status improvement 
–  Relationship status improvement 
–  Psychological distress 
Non-cancer Pain Data 
•  n = 4,893; 26 studies (1 RCT) 
•  Efficacy 
–  “…weak evidence suggests that patients who are 
able to continue opioids long-term experience 
clinically significant pain relief. 
–  “Whether quality of life or functioning improves is 
inconclusive.” 
•  Toxicity: 
–  23% discontinued oral opioids due to adverse 
events 
Noble	  M,	  et	  al.	  Cochrane	  Database	  Syst	  Rev.	  2010	   RCT:	  randomized	  controlled	  clinical	  trial	  
The 1 RCT for CNCP 
•  Randomized, open-label, parallel group 
–  Transdermal fentanyl vs. PO morphine SR 
–  13-month duration 
•  Patients 
–  Chronic low back pain (n = 680) in need of strong 
opioid (investigator determined) 
–  Exclusion criteria 
•  Regular strong opioid use within 4 weeks of entry 
•  History of alcohol or substance abuse 
–  Mean age: 54 years; 61% female 
Allan	  L,	  et	  al.	  Spine	  2005;30:2484-­‐2490	  
CNCP,	  chronic	  non-­‐cancer	  pain	  
Transdermal	  Fentanyl	  
(n	  =	  338)	  
SR	  Morphine	  
(n	  =	  342)	  
StarKng	  dose	   25	  mcg/hr	   60	  mg/day	  
Final	  dose,	  mean	  (range)	   57	  mcg/hr	  (12.5	  –	  250)	   140	  mg/day	  (6	  –	  780)	  
VAS	  endpoint	  scores	   56.0	   55.8	  
No	  loss	  of	  work	  (n	  =	  131)*	  
	  	  baseline	  
	  	  endpoint	  
	  
35%	  
59%	  
	  
49%	  
67%	  
QOL,	  physical	  health	  (SF-­‐36)	  
	  	  baseline	  	  
	  	  endpoint	  
	  
25.8	  
30.8	  
	  
25.7	  
30.5	  
QOL,	  mental	  health	  (SF-­‐36)	  
	  	  baseline	  
	  	  endpoint	  
	  
41.2	  
41.1	  
	  
43.0	  
44.2	  
ConsKpaKon	  	   52%	   65%	  
*Due	  to	  70%	  non-­‐working	  subjects	  at	  baseline	  (e.g.	  reKred,	  disabled)	  
p	  <	  0.05	  
Zero	  cases	  of	  death	  or	  addicKon.	  
Allan	  L,	  et	  al.	  Spine	  2005;30:2484-­‐2490	  
Comments on Allan, et al. 
•  Average opioid dose > 120 mg MED “max” dose 
recommended by some 
–  Does NOT account for breakthrough IR opioids used by 
50% (dosing not provided in manuscript) 
–  No data break down on very high dose subjects 
•  Highest dose 780 mg MED 
•  Both groups experienced improvement in physical 
QOL 
–  Numerically, increased ability to work 
•  Likely underpowered  
•  No difference in mental health QOL 
•  No serious toxicity over 13 months of opioid use 
Summary 
•  Patients with and without cancer tolerate high 
doses of opioids (in clinical trial settings) 
–  Little to no evidence for risk of overdose or 
respiratory depression 
•  No apparent ceiling effect on opioids 
–  Wide range of dosing, including some very high 
doses 
•  Endpoints, and trial design limit 
generalizability of efficacy 
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Which of the following morphine milligram 
equivalent (MME) doses is the maximum you 
feel comfortable prescribing on a regular basis 
for chronic pain? 
A.  50 
B.  75  
C.  90 
D.  120  
E.  200  
50 75
	  
90 12
0	  
20
0	  
0% 0% 0%0%0%
Which	  of	  the	  following	  best	  describes	  
your	  posiKon?	  
A.  I believe there IS a 
maximum opioid dose 
that should not be 
exceeded in the 
treatment of chronic 
nonmalignant pain. 
B.  I do NOT believe there is 
a maximum opioid dose 
in the treatment of 
chronic nonmalignant 
pain.  
I	  b
eli
ev
e	  t
he
re	  
IS	  
a	  m
ax
...
I	  d
o	  N
OT
	  be
lie
ve
	  th
ere
	  i..
.
0%0%
The Controversy 
•  For over 20 years, opioid therapy for chronic 
pain has been controversial 
•  What can we agree on? 
–  Chronic pain has substantial negative effect and 
patients need and deserve compassionate care 
based on evidence-based medicine 
–  Increase in prescribing of opioids has led to 
increase in diversion, addiction, and fatal 
overdoses 
 
 Von Korff M, Kolodny A, Deyo RA, et al.  Long-term opioid therapy 
reconsidered.  Ann Inter Med. 2011;155(5):325-8. 
The Patient 
•  48-year-old female with non-malignant chronic pain resulting 
from failed back surgery s/p motor vehicle accident 6 years ago 
•  Treated with non-opioid analgesics and non-pharmacologic 
interventions with little success; when unable to work she was 
considered a suitable candidate for opioid treatment of chronic 
pain 
•  She reported good response to opioid therapy and had 
improvement of function at 1 year 
–  Pain score was reduced from 9/10 to 6/10 and she was able to return to 
work 
–  Treatment at that time was oxycodone ER 20 mg every 12 hours. 
The Patient 
•  After 2 years of opioid therapy, her mother developed 
Alzheimer’s disease and the patient became her caregiver 
•  Pain relief was not as good as it used to be and she 
requested a dose increase of the oxycodone 
•  Over the next 4 years, she requested dose increases on a 
regular basis because her pain and functioning continued to 
worsen 
•  Current medication is oxycodone ER 80 mg every 8 hours 
(____morphine equivalent dose) 
•  She is house bound, mother has died, can’t get out of bed in 
the morning, nothing is working 
•  What do you do? 
Describe the data supporting the rationale 
that high doses of opioids do not improve 
outcomes 
Effectiveness of Long-Term  
Opioid Therapy 
•  Long-lasting benefits for patients are NOT 
supported by strong evidence 
•  Controlled trials lasting 1-6 months suggest 
moderate analgesia compared with placebo 
–  No long-term studies have determined if efficacy is 
maintained 
–  Most studies completed have industry support and 
evidence of bias  
Hegmann KT, Weiss MS, Bowden K, et al.  ACOEM practice guidelines: 
opioids for treatment of acute, subacute, chronic, and postoperative pain. J 
Occup Environ Med. 2014 Dec;56(12):e143-59. 
 
Effectiveness of Long-Term  
Opioid Therapy 
•  Studies of long-term opioid therapy versus other 
treatments are few; limited advantages for opioids 
•  American Pain Society/American Academy of 
Pain Medicine 2009 evaluation of evidence 
–  21 out of 25 recommendations based on low-quality 
evidence 
•  Quality evidence other treatments are equivalent 
or superior to opioids in chronic pain 
 
Chou R, Ballantyne JC, Fanciullo GJ, et al.  Research gaps on use of opioids for chronic noncancer 
pain: findings from a review of the evidence for an American Pain Society and American Academy of 
Pain Medicine clinical practice guideline. J Pain. 2009; 10:147–159.  
 
Hegmann KT, Weiss MS, Bowden K, et al.  ACOEM practice guidelines: opioids for treatment of acute, 
subacute, chronic, and postoperative pain. J Occup Environ Med. 2014 Dec;56(12):e143-59. 
 
Effectiveness of Long-Term  
Opioid Therapy 
•  No trials document improved objective 
functional outcomes; more than 100 trials 
document many adverse effects 
•  Survey of primary care patients with chronic 
pain treated with opioids state they continue 
to have moderate to severe pain and 
functioning is poor 
Hegmann KT, Weiss MS, Bowden K, et al.  ACOEM practice guidelines: opioids for 
treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ 
Med. 2014 Dec;56(12):e143-59. 
 
Sullivan MD, Von Korff M, Banta-Green C,  et al.  Problems and concerns of 
patients receiving chronic opioid therapy for chronic noncancer pain. Pain. 2010; 
149:345–353. 
Effectiveness of Long-Term  
Opioid Therapy 
•  2015 evaluation of effectiveness and harm of long-term 
opioids for chronic pain through published randomized 
trials and observational studies 
–  NO study of opioid therapy vs. no opioids evaluated 
long-term (> 1 year) outcomes related to pain, 
function, quality of life, abuse or addiction 
–  Good and fair-quality observational studies suggest 
increased risk for overdose, myocardial infarction, 
fractures, substance abuse, sexual dysfunction 
–  For some harms, higher doses = increased risk 
 
 
Chou R, Turner JA, Devine, EB, et al.  The effectiveness and risks of long-term 
opioid therapy for chronic pain: a systematic review for a National Institutes of 
Health Pathways to Prevention Workshop. Ann Intern Med. 2015 ;162(4):276-86.  
Unproven efficacy, neglected safety? 
•  Study evaluated hypotheses 
–  There is no strong evidence-based foundation for the conclusion 
that long-term opioid treatment of chronic nonmalignant pain is 
effective 
–  Main problem associated with the safety of such treatment has 
been neglected -  assessment of the risk of addiction  
•  Scientometric analysis of the articles representing clinical 
research  
–  Quality of presented evidence (type of study) 
–  Duration of the treatment phase 
–  Sufficiency of representation of addiction was assessed by 
counting the number of articles published 
Kissin I. Long-term opioid treatment of chronic nonmalignant pain: unproven 
efficacy and neglected safety? J Pain Res. 2013; 6: 513–529. 
Unproven efficacy, neglected safety? 
•  Results 
–  No randomized controlled trial with opioid treatment lasting greater than 3 
months was found 
–  All studies with a duration of opioid treatment greater than 6 months (n = 
16) were conducted without a proper control group 
–  Profound differences in the number of addiction articles related 
specifically to chronic nonmalignant pain patients and to opioid addiction 
in general 
–  Inadequate number of chronic pain-related publications were observed 
•  Conclusion 
–  No strong evidence-based foundation for the conclusion that long-
term opioid treatment of chronic nonmalignant pain is effective 
–  Little data evaluating addiction from opioid treatment of chronic 
nonmalignant pain are available 
Kissin I. Long-term opioid treatment of chronic nonmalignant pain: unproven 
efficacy and neglected safety? J Pain Res. 2013; 6: 513–529. 
Consequences of High Dose 
Opioids 
•  Chronic opioid therapy is associated with 
the development of tolerance to analgesic 
effects 
•  Opioid therapy may also paradoxically 
induce abnormal pain sensitivity, including 
hyperalgesia and allodynia 
•  Increasing opioid doses may not improve 
function and pain control  
King T, Ossipov MH, Vanderah TW,  et al.  Is paradoxical pain induced by sustained opioid exposure 
an underlying mechanism of opioid antinocieceptive tolerance? Neurosignals 2005;14:194-205. 34.  
Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 
2002;10:213-217. 35.  
Ossipov MH, Lai J, King T, et al. Underlying mechanism of pronocieptive consequences of prolonged 
morphine exposure. Biopolymers 2005;80(2-3):319-324.  
Describe the data supporting the rationale 
that high doses of opioids increase toxicity 
Risks of Higher Doses 
 
•  Dunn et al. estimated the rates of opioid overdose and 
the association with an average prescribed daily opioid 
dose among patients receiving medically prescribed, 
long-term opioid therapy in an HMO setting 
•  Cox proportional hazards models were used to 
estimate overdose risk as a function of average daily 
opioid dose (morphine equivalents) received at the 
time of overdose. 
•  9940 persons who received 3 or more opioid 
prescriptions within 90 days for chronic noncancer 
pain between 1997 and 2005 
Dunn KM, Saunders KW, Rutter CM,  et al.  Opioid prescriptions for chronic 
pain and overdose: a cohort study.  Ann Intern Med. 2010;152(2):85-92 
Risks of Higher Doses 
•  Average daily opioid dose over the previous 90 days obtained from 
automated pharmacy data. Primary outcomes--nonfatal and fatal 
overdoses--were identified through diagnostic codes from inpatient and 
outpatient care and death certificates 
•  51 opioid-related overdoses were identified, including 6 deaths 
–  Patients receiving 1 to 20 mg/d of opioids (0.2% annual overdose 
rate),  
–  Patients receiving 50 to 99 mg/d had a 3.7-fold increase in overdose 
risk (95% CI, 1.5 to 9.5) and a 0.7% annual overdose rate 
–  Patients receiving 100 mg/d or more had an 8.9-fold increase in 
overdose risk (CI, 4.0 to 19.7) and a 1.8% annual overdose rate. 
•  Conclusion 
–   Patients receiving higher doses of prescribed opioids are at 
increased risk for overdose, which underscores the need for close 
supervision of these patients 
Dunn KM, Saunders KW, Rutter CM,  et al.  Opioid prescriptions for chronic 
pain and overdose: a cohort study.  Ann Intern Med. 2010;152(2):85-92 
Association of Maximum Dose with 
Risk of Death 
•  Examination of  the association of maximum prescribed daily opioid 
dose and dosing schedule (“as needed,” regularly scheduled, or 
both) with risk of opioid overdose death among patients with cancer, 
chronic pain, acute pain, and substance use disorders 
•  Case-cohort study;  Veterans Health Administration, 2004-2008 
•  All unintentional prescription opioid overdose decedents (n = 750) 
and a random sample of patients (n = 154,684) among those 
individuals who used medical services in 2004 or 2005 and received 
opioid therapy for pain 
•  Measure associations of opioid regimens (dose and schedule) with 
death by unintentional prescription opioid overdose in subgroups 
Bohnert A, Valenstein M. Bair M, et al. Association between opioid prescribing 
patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321. 
Association of Maximum Dose with 
Risk of Death 
•  Frequency of fatal overdose over the study period among individuals treated 
with opioids was estimated to be 0.04% 
•  Risk of overdose death directly related to the maximum prescribed daily dose  
•  Adjusted hazard ratios (HRs) associated with a maximum prescribed dose of 
100 mg/d or more, compared with the dose category 1 mg/d - 20 mg/d 
–  Among those with substance use disorders, adjusted HR = 4.54  
–  Among those with chronic pain, adjusted HR = 7.18  
–  Among those with acute pain, adjusted HR = 6.64 
–  Among those with cancer, adjusted HR = 11.99  
–  Receiving both as-needed and regularly scheduled doses was not associated with 
overdose risk after adjustment. 
•  Among patients receiving opioid prescriptions for pain, higher opioid doses 
were associated with increased risk of opioid overdose death 
Bohnert A, Valenstein M. Bair M, et al. Association between opioid prescribing 
patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321. 
Impact of High-dose Opioid Analgesics 
on Overdose Mortality 
•  Prospective observational cohort in North Carolina with one year follow-up 
–  Quantification of dose-dependent overdose mortality using prescription monitoring 
program 
–  Examination of the contributions of benzodiazepines and extended release opioid 
formulations to mortality 
•  Residential population of North Carolina (n  =  9,560,234), with 2,182,374 
opioid analgesic patients 
•  Exposure was dispensed prescriptions of solid oral and transdermal 
opioid analgesics; person-years calculated using intent-to-treat principles 
•  Outcome was overdose deaths involving opioid analgesics in a primary or 
additive role. Poisson models were created, implemented using 
generalized estimating equations. 
Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid  
analgesics on overdose mortality.Pain Med. 2015 Sep 1. doi: 10.1111/pme.12907.  
Impact of High-dose Opioid Analgesics 
on Overdose Mortality 
•  Results 
–  Opioid analgesics were dispensed to 22.8% of residents 
–  Among licensed clinicians, 89.6% prescribed opioid 
analgesics, and 40.0% prescribed ER formulations 
–  629 overdose deaths, half of which had an opioid analgesic 
prescription active on the day of death 
–  Of 2,182,374 patients prescribed opioids, 478 overdose 
deaths were reported (0.022% per year) 
–  Mortality rates increased gradually across the range of 
average daily MED 
Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid  
analgesics on overdose mortality.Pain Med. 2015 Sep 1. doi: 10.1111/pme.12907.  
Impact of High-dose Opioid Analgesics on 
Overdose Mortality 
•  Results 
–  80.0% of opioid analgesic patients also received benzodiazepines  
–  Rates of overdose death among those co-dispensed 
benzodiazepines and opioid analgesics were ten times higher (7.0 
per 10,000 person-years, 95 percent CI: 6.3, 7.8) than opioid 
analgesics alone (0.7 per 10,000 person years, 95 percent CI: 0.6, 
0.9). 
•  Conclusions 
–  Dose-dependent opioid overdose risk among patients increased 
gradually and did not show evidence of a distinct risk threshold 
–  Urgent need for guidance about combined classes of medicines to 
facilitate a better balance between pain relief and overdose risk 
Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid  
analgesics on overdose mortality.Pain Med. 2015 Sep 1. doi: 10.1111/pme.12907.  
Patients Prescribed Opioids 
Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose. Ann 
Intern Med 2010;152:85–92. 
Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid 
overdose-related deaths. JAMA 2011;305:1315–21. 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm 
Identify potential safety concerns with 
patients taking high doses of opioids 
Safety Concerns 
•  Overdose and death (co-prescribe naloxone) 
•  Addiction 
•  Co-prescribing with other CNS depressants 
•  Accidents 
•  Fractures, osteoporosis 
•  Sexual dysfunction, hypogonadism 
•  Dysphoria, depression 
•  Immunologic effects 
Hegmann KT, Weiss MS, Bowden K, et al.  ACOEM practice guidelines: opioids for 
treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 
2014 Dec;56(12):e143-59. 
 
Cytochrome P450 Defects – A 
Cause of High Doses? 
•  CYP-3A4, CYP-2D6 and CYP-2C9 defects 
•  20 to 30% of pain patients likely have a genetic opioid 
metabolic defect (GOMD)  
•  Some opioids are “pro” drugs that must be converted 
to a metabolite to be effective (i.e., hydrocodone, 
codeine, tramadol and, to a lesser extent, oxycodone) 
•  Some opioids, including tapentadol and oxymorphone, 
mostly bypass the CYP450 system and are 
metabolized by glucoronidation 
•  Practitioner can screen patients for a possible GOMD 
by asking simple questions; routine laboratory 
screening not recommended 
Tennant F.  Making sense of  cytochrome P450. Available online at  
http://www.practicalpainmanagement.com/treatments/pharmacological/
opioids/making-practical-sense-cytochrome-p450?page=0,1 
	  

Where is Tennessee? 
•  IMS Health’s National Prescription Audit, 2012 
•  Prescribing rates per 100 persons 
State Opioid Pain 
Relievers; 
Rank 
Long-acting 
or extended 
release; Rank 
High 
dose 
opioids; 
Rank 
Benzodiazepines; 
Rank 
TENNESSEE 142.8 / 2nd 18.2 / 5th 8.7 / 2nd 61.4 / 3rd 
VIRGINIA 77.5 / 29th 9.9 / 36th 4.7 / 21st 33.5 / 31st 
Paulozzi LJ, Mack KA, Hockenberry JM. Variation among states in 
prescribing of opioid pain relievers and benzodiazepines – United 
States, 2012. J Safety Res. 2014;51:125-9. 
Exit Plan - Tapering 
https://www.ghc.org/all-sites/guidelines/
chronicOpioid.pdf 
Conclusions 
•  Adverse events and death associated with opioid analgesic 
use have increased substantially over the past 20 years 
•  MED recommendations are decreasing in new guidelines to 
70 MED or below – Tennessee remains at 120 MED 
•  Risk of opioid-related adverse events increases with dose 
•  Doses greater than 50 mg MED daily show elevated risk, and 
little evidence of benefit 
•  Highest risk appears to be in those on more than 200 mg 
MED daily 
•  All patients on chronic opioids should be stratified by risk 
Conclusions 
•  Having an exit strategy is a must 
•  Implement a structured stepwise program to reduce dose in 
patients on high dose 
•  Tapering to lower doses, opioid rotation, or change to 
buprenorphine are options 
•  Safety and effectiveness of opioid therapy for chronic non-
cancer pain should be routinely evaluated by the prescriber 
•  Universal precautions should be used in every patient, every 
time when prescribing opioids for chronic pain 
•  CO-PRESCRIBE NALOXONE! 
Next Friday afternoon… 
•  53-year-old female with non-malignant chronic pain 
resulting from failed back surgery s/p motor vehicle 
accident 8 years ago presents to establish care after 
her PCP retired 
•  Oxycodone ER 60 mg Q 12 hours (2 tabs remaining) 
•  Hydrocodone 5/325 (14 tabs remaining from a 3 
month old prescription s/p dental work) 
•  Clonazepam, sertraline, HCTZ 
•  Function  
–  Improved with dose reduction from 240 mg/day oxycodone 
over last 6 months 
–  Returned to work 
What change would you make to this patient’s 
opioid regimen in addition to co-prescribing 
naloxone? 
A.  No new Rx until reviewing 
medical records from retired 
PCP 
B.  Continue oxycodone ER 60 
mg Q 12 
C.  Decrease oxycodone ER to 
40 mg Q 12 
D.  Change to morphine SR 60 
mg Q 8 hours 
E.  Change to methadone 5 mg Q 
6 hours 
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